Sector News

Latest Allergan buzz puts Ireland’s Jazz in its dealmaking sights

September 8, 2014
Life sciences
Forget Salix Pharmaceuticals and long-gone Shire. No. 1 on Allergan’s list of defensive acquisition prospects could be Ireland’s Jazz Pharmaceuticals.
 
The Dublin drugmaker is the most viable option for Allergan, which hopes a pickup of its own will thwart a hostile takeover attempt from Valeant, three industry bankers told dealReporter (as cited by Benziga).
 
Jazz, with its tax-advantaged Irish address, could be the lifeline Allergan’s been looking for. Analysts have long said bulking up could help the Botox-maker fend Valeant off, and a lowered tax rate would negate one of the proposed benefits of a merger with the Canadian drugmaker.
 
That’s not to mention Jazz’s own merits, which include some of the best profit margins in the drug industry. The tiny company has been beefing itself up lately, too; in December it paid $1 billion to buy Italy-based Gentium in a deal analysts said could make Jazz a more attractive target.
 
But plenty of rumors have been flying since CEO J. Michael Pearson’s deal machine made its first bid for Allergan this spring. First in the spotlight was Ireland’s Shire, which AbbVie quickly moved in to snap up in July. More recently, a potential move for North Carolina’s Salix had industry-watchers abuzz.
 
And to say Jazz is a rumor-mill regular would be an understatement. The specialty pharma, which makes the narcolepsy treatment Xyrem, has long made the list of pharma’s perennial takeover targets, though so far, it’s survived pharma’s tax inversion frenzy.
 
Still, speculation fueled a 7% rise in Jazz’ stock price Friday, and thanks to Ireland’s buyout rules, it may not be long before we know if the two parties really are engaged in M&A talks.
 
As Sterne Agee analyst Shibani Malhotra wrote in a note to clients, the Irish Takeover Panel’s rules require that an announcement regarding the offer be made in the event of an “anomalous movement in share price.”
 
“In our view there should be further clarity in the next few business days with either a disclosure confirming takeover talks or a lack of an announcement following what appears to be an Irish Takeover Panel disclosure triggering event,” he wrote.
 
By Carly Helfand
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend